Hispanic Broadcasting

Hispanic Broadcasting Newswire

Comprehensive Real-Time News Feed for Hispanic Broadcasting.

Results 1 - 20 of 183 in Hispanic Broadcasting

  1. Best And Worst Performing S&P 500 Stocks Year-To-DateRead the original story w/Photo

    Yesterday | Seeking Alpha

    For those looking to catch up on 2015s winners and losers over the long Memorial Day weekend, below is a list of the 40 best and worst performing stocks in the S&P 500 YTD. As shown, Netflix tops the list of winners with a gain of 82.68%, followed by Skyworks at 45.26% and Hospira at 43.98%.


  2. Barclays: Pfenex Is Worth $28/ShareRead the original story

    Monday May 18 | Benzinga

    In a report published Monday, Barclays analysts initiated coverage of Pfenex, Inc. with an Overweight rating and price target of $28. The analysts believe the stock offers an attractive investment option, given the company's "differentiated platform for the development of biosimilars and complex generics."


  3. Hospira Shareholders Approve Merger Of And Pfizer At Special MeetingRead the original story

    Wednesday May 13 | BioSpace

    The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions.


  4. Pfenex Reports First Quarter 2015 Results And Provides Business UpdateRead the original story

    Wednesday May 13 | BioSpace

    As we have previously disclosed, under the terms of the collaboration, Pfenex received a in milestone payments along with tiered double digit royalties. Additionally, in the first quarter of 2015 we achieved an important milestone with the initiation of a Phase 1 trial for PF530, our biosimilar candidate to Betaseron.


  5. a Medical supplier files suit against local hospital systemRead the original story w/Photo

    Monday May 11 | Business Journal

    Hospira Worldwide Inc. has sued Harnett Health System, alleging the non-profit health care provider failed to pay for more than $123,000 in medical supplies. Hospira Worldwide Inc. has filed a lawsuit against Harnett Health System, alleging the nonprofit health care provider failed to pay for more than $123,000 in medical supplies.


  6. Biosimilars Access and Education Taking Center Stage with First Biosimilars in the WingsRead the original story w/Photo

    Wednesday May 6 | jdsupra.com

    Two new voices have emerged with goals to help expand patient access and information about biosimilars in the United States - the Biosimilars Forum and the Biosimilars Council, discussed below. Along with these voices, the New York State Bar Association's Food, Drug and Cosmetic Law Section Biologics Law Committee is working with NYSBA's Health Law Section, Committee on Medical Research and Biotechnology , to take a look at and consider legislative changes for state laws regarding substitution, as well as reimbursement and biological analytics.


  7. Hospira Sacks 100 EmployeesRead the original story

    Wednesday May 6 | BioSpace

    Drug maker Hospira officially put 100 workers in Clayton on notice that they would be laid off. On Jan. 12, Hospira, based in Lake Forest, Illinois, disclosed it would shutter the Clayton manufacturing plant and now filed the official WARN with the North Carolina Department of Commerce.


  8. Pamela PuryearRead the original story w/Photo

    Friday May 1 | HR Magazine

    For Pamela Puryear, VP of organizational development and chief talent officer at Hospira Inc., a learning culture is just good business. Even in a family of Ph.D.s, Pamela Puryear is an overachiever.


  9. Pfizer's Healthy Dividend Helps Against The Strong Dollar BlahsRead the original story w/Photo

    Thursday Apr 30 | Seeking Alpha

    Pfizer beat market estimates on Q1 2015 revenues- $10.86 billion versus $10.81 billion- but continuing dollar strength coupled with weakness in the euro is compounding the effect currency translations are having on fiscal 2015 full-year guidance. According to the company, the FX impact on total reported revenues was a negative 7%.


  10. Will Pfizer (NYSE: PFE) Break in Two?Read the original story w/Photo

    Thursday Apr 30 | Learn Bonds

    Pfizer reported first quarter profit of $0.51 per share on $10.86 billion of revenue Tuesday -beating estimates of $0.49 per share. The performance was largely driven by strong demand for its vaccine and cancer drugs.


  11. Regulators: skip clinical data and extrapolate biosimilar indicationsRead the original story w/Photo

    Wednesday Apr 29 | In-PharmaTechnologist.com

    Peter Richardson, Head of Quality at the EMA, speaks at the EGA-EBG meeting in London last week. Other speakers : Martina Weise, EMA; Steinar Madsen, Norwegian Medicines Agency; Sumant Ramachandra, Hospira; Joerg Windisch, EBG.


  12. Pfizer Reports First-Quarter 2015 ResultsRead the original story w/Photo

    Tuesday Apr 28 | Insurance News Net

    The company manages its commercial operations through two distinct businesses: an Innovative Products business and an Established Products business. The Innovative Products business is composed of two operating segments: the Global Innovative Pharmaceutical segment and the Global Vaccines, segment .


  13. Hospira Sales Jump After Announcement of Giant BuyoutRead the original story w/Photo

    Wednesday Apr 29 | Patch.com

    Net sales for Lake Forest-based Hospira jumped 11.8 percent to $1.2 billion in the first quarter of 2015. In the midst of a merger with Pharmaceutical giant Pfizer who offered to buy in the company in February, the numbers beat expectations, the Daily Herald reports.


  14. Commerce Commission to consider pharmaceuticals mergerRead the original story

    Tuesday Apr 28 | Scoop

    The Commerce Commission has received an application from Pfizer Inc. seeking clearance to acquire all of the shares in Hospira Inc. Pfizer is a global pharmaceutical company with a focus on the research and development of new pharmaceutical products. In New Zealand, Pfizer sells a range of consumer and prescription pharmaceuticals and operates through its subsidiaries Pfizer New Zealand Limited and Pfizer PFE.


  15. Alibaba Group Holding (BABA), Hospira (HSP), Philip Morris...Read the original story w/Photo

    Tuesday Apr 28 | Insider Monkey

    Deepak Gulati 's Switzerland-based fund, Argentiere Capital recently disclosed its equity holdings as of the end of the first quarter in a filing with the SEC. The fund initiated a number of new stakes, the most noteworthy being new positions in Alibaba Group Holding Ltd , Hospira, Inc. , Philip Morris International Inc. , JPMorgan Chase & Co.


  16. Hospira (HSP) Releases Earnings Results, Beats Estimates By $0.44 EPSRead the original story

    Tuesday Apr 28 | AmericanBankingNews.com

    Hospira issued its quarterly earnings data on Tuesday. The company reported $0.97 earnings per share for the quarter, beating the analysts' consensus estimate of $0.53 by $0.44, AnalystRatingsNetwork.com reports.


  17. Hospira Reports First-Quarter 2015 ResultsRead the original story

    Dec 31, 2014 | Digital Post Production

    On a U.S. Generally Accepted Accounting Principles basis, first-quarter 2015 diluted earnings per share were "Hospira started out the year with very strong sales and profitability, driven primarily by continued momentum in our Specialty Injectable Pharmaceuticals business," said , chief executive officer. "In addition to our strong financial performance, we made significant progress on many fronts, including enhancing our biosimilars pipeline, launching new generic injectable products and advancing our device strategy.


  18. Lake Forest's Hospira beats sales expectationsRead the original story w/Photo

    Tuesday Apr 28 | Daily Herald

    Hospira Inc. , a provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today reported first-quarter 2015 results that beat expectations. Pharmaceutical giant Pfizer offered to buy the Lake Forest company in February for about $15.23 billion.


  19. Hospira profit beats as injectables remain strongRead the original story w/Photo

    Tuesday Apr 28 | MarketWatch

    Hospira Inc. reported a sharply better-than-expected profit in its first quarter as its injectable drugs continued to drive growth. The results come as Hospira moves forward with plans to sell itself to Pfizer Inc. for about $16 billion.


  20. Hospira Recalls Single Lot of Bupivacaine HCl InjectionRead the original story w/Photo

    Monday Apr 27 | Philly.com

    Hospira, Inc., a provider of injectable drugs and infusion technologies located in Lake Forest, Ill., has issued a voluntary recall of one lot of Preservative-Free Bupivacaine HCl Injection due to possible contamination with iron oxide. The lot was distributed from July 2014 to September 2014.